S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
Log in

ASX:RAPResapp Health Stock Price, Forecast & News

A$0.18
-120,035.82 (-100.00 %)
(As of 04/9/2020 04:00 PM ET)
Add
Compare
Today's Range
A$0.18
Now: A$0.18
A$0.19
50-Day Range
A$0.07
MA: A$0.17
A$0.26
52-Week Range
A$0.06
Now: A$0.18
A$0.42
Volume1.68 million shs
Average VolumeN/A
Market Capitalization$127.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company delivers mobile software apps in various clinical settings, including telehealth, emergency, urgent care, and primary care. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was founded in 2014 and is headquartered in Brisbane, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry Health Information Services
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 7 3724 0035

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59,224.00
Cash FlowA$0.01 per share
Book ValueA$0.01 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$127.06 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RAP News and Ratings via Email

Sign-up to receive the latest news and ratings for RAP and its competitors with MarketBeat's FREE daily newsletter.


Resapp Health (ASX:RAP) Frequently Asked Questions

Has Resapp Health been receiving favorable news coverage?

Media headlines about RAP stock have trended very negative recently, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Resapp Health earned a news impact score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutResapp Health.

Who are some of Resapp Health's key competitors?

Who are Resapp Health's key executives?

Resapp Health's management team includes the following people:
  • Dr. Anthony Keating, CEO, MD & Director
  • Ms. Kay Taylor Ph.D., VP of Strategic Devel. & Operations
  • Dr. Udantha Abeyratne, Chief Scientist & Scientific Advisor
  • Ms. Nicki Farley, Company Sec. (Age 43)
  • Dr. Clas Källander, Founder and Director of R&D of Cavidi AB

What is Resapp Health's stock symbol?

Resapp Health trades on the ASX under the ticker symbol "RAP."

What is Resapp Health's stock price today?

One share of RAP stock can currently be purchased for approximately A$0.18.

How big of a company is Resapp Health?

Resapp Health has a market capitalization of $127.06 million and generates $59,224.00 in revenue each year.  View additional information about Resapp Health.

What is Resapp Health's official website?

The official website for Resapp Health is http://www.resapphealth.com.au/.

How can I contact Resapp Health?

The company can be reached via phone at 61 7 3724 0035.

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel